Prevalence of obesity and cardiovascular disease in adults with type 2 diabetes and use of diabetes medication in Germany: A claims data study
Authors' conclusion
In this retrospective claims database study, more than two thirds of patients with T2D also had CVD, obesity, or both CVD and obesity. GLP-1 RA and SGLT2 inhibitor use remained low.
Study context
- Population
- Adults (≥18 years) with T2D among 4.5 million publicly insured German residents, 2014–2020
- Outcome
- Prevalence of CVD and obesity in patients with T2D
- Follow-up
- 2020
Methodological detailsclaims data, extrapolated to German population by age and sex
- Claims data
- Extrapolated to German population by age and sex
Main finding
As reported in the abstract
Prevalence among patients with T2D
Prevalence of T2D
11.4%
T2D with cardiovascular disease (CVD)
53.0%
T2D with obesity
39.3%
T2D with CVD and obesity
20.9%
Observational data: associations, not effects.
Further findings
Change since 2014 in patients with T2D · 2014-2020
- CVD increase
- 1.4%
- Obesity increase
- 4.5%
- CVD with obesity increase
- 2.7%
Incidence of T2D · 2020
- Incidence of T2D
- 1.0%
- Incident T2D with CVD
- 42.9%
- Incident T2D with obesity
- 37.9%
- Incident T2D with CVD and obesity
- 15.8%
Antidiabetic treatment in prevalent T2D · 2020
- GLP-1 RA
- 4.9%
- SGLT2i
- 9.7%
- GLP-1 RA and/or SGLT2i
- 13.0%
- GLP-1 RA and/or SGLT2i, with CVD
- 12.9%
- GLP-1 RA and/or SGLT2i, without CVD
- 13.2%
- GLP-1 RA and/or SGLT2i, with obesity
- 19.4%
- GLP-1 RA and/or SGLT2i, without obesity
- 9.0%
Original publication
Prevalence of obesity and cardiovascular disease in adults with type 2 diabetes and use of diabetes medication in Germany: A claims data study. Diabetes Obes Metab. Published 19 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →